Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metvixia daylight photodynamic therapy vs conventional photodynamic therapy in actinic keratosis of the scalp
2014-003602-32Phase 3Completed
- Sponsor
- CHU de Limoges
- Start
- Jun 2015
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methyl aminolevulinate in actinic keratosis (AK) (2 arms), sponsored by CHU de Limoges. Primary endpoint: Number of disappeared actinic keratosis lesions at 3 months. Started Jun 2015; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2014-003602-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003602-32.